TransThera Sciences (Nanjing), Inc. (TransThera) has finalised the placement of 3.84 million new H shares at HK$40.83 each, generating gross proceeds of HK$156.62 million. Net of fees and expenses, the company will receive approximately HK$152.13 million, equating to a net issue price of HK$39.66 per share.

The newly issued shares account for 1.23% of TransThera’s enlarged H-share base and 0.94% of total issued share capital. All shares were subscribed by at least six professional or institutional investors, none of whom became substantial shareholders.

Use of proceeds: • Around 90% (HK$136.92 million) will fund development of new indications for the core product, Tinengotinib. • The remaining 10% (HK$15.21 million) is earmarked for working capital and general corporate purposes.

Post-placement shareholding structure: • Unlisted shares remain unchanged at 95.23 million, representing 23.35% of enlarged capital. • H shares rise to 312.69 million (76.65% of enlarged capital), comprising 80.60 million held by core connected persons, 3.84 million held by the new placees, and 228.25 million held by other shareholders. • Total issued shares increase to 407.92 million.

The transaction was arranged by a sole overall coordinator and placing agent, with completion confirmed on 27 May 2026 following satisfaction of all conditions under the placing agreement.